IN2012DN03338A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03338A
IN2012DN03338A IN3338DEN2012A IN2012DN03338A IN 2012DN03338 A IN2012DN03338 A IN 2012DN03338A IN 3338DEN2012 A IN3338DEN2012 A IN 3338DEN2012A IN 2012DN03338 A IN2012DN03338 A IN 2012DN03338A
Authority
IN
India
Prior art keywords
factor
antibody
antigen binding
binding fragment
crystal structure
Prior art date
Application number
Inventor
Menno Van Lookeren Campagen
Christian Wiesmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03338A publication Critical patent/IN2012DN03338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention is directed towards the co-crystal structure of Factor D and an anti-Factor D antibody or an antigen binding fragment thereof.
IN3338DEN2012 2009-11-04 2010-11-04 IN2012DN03338A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US28171609P 2009-11-20 2009-11-20
PCT/US2010/055509 WO2011057014A1 (en) 2009-11-04 2010-11-04 Co-crystal structure of factor d and anti-factor d antibody

Publications (1)

Publication Number Publication Date
IN2012DN03338A true IN2012DN03338A (en) 2015-10-23

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3338DEN2012 IN2012DN03338A (en) 2009-11-04 2010-11-04

Country Status (14)

Country Link
US (1) US20110165648A1 (en)
EP (1) EP2496695A1 (en)
JP (1) JP2013509866A (en)
KR (1) KR20120120153A (en)
CN (1) CN102666850A (en)
AR (1) AR078886A1 (en)
BR (1) BR112012011607A2 (en)
CA (1) CA2782481A1 (en)
IN (1) IN2012DN03338A (en)
MX (1) MX2012005430A (en)
RU (1) RU2012122700A (en)
TW (1) TW201121993A (en)
WO (1) WO2011057014A1 (en)
ZA (1) ZA201202602B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (en) * 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
CR20160561A (en) 2014-05-01 2017-05-03 Genentech Inc ANTI-FACTOR D ANTIBODY VARIATIONS AND THEIR USES
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (en) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Butyrylcholinesterase amphoteric ionic polymer conjugate
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CA3003647A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
CA3011819A1 (en) * 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018250695A1 (en) * 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
FI903489A0 (en) 1988-11-11 1990-07-10 Medical Res Council LIGANDER MED EN ENDA SEKTION, RECEPTORER INNEHAOLLANDE NAEMNDA LIGANDER, FOERFARANDEN FOER DERAS FRAMSTAELLNING SAMT ANVAENDNING AV LIGANDERNA OCH RECEPTORERNA.
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DK0494955T3 (en) 1989-10-05 1998-10-26 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
JP4753578B2 (en) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド Synthetic antibody phage library
SI2097455T1 (en) * 2006-11-02 2015-03-31 Genentech, Inc. Humanized anti-factor d antibodies
AR066660A1 (en) * 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
CR20170001A (en) * 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES

Also Published As

Publication number Publication date
CN102666850A (en) 2012-09-12
CA2782481A1 (en) 2011-05-12
US20110165648A1 (en) 2011-07-07
ZA201202602B (en) 2013-06-26
AR078886A1 (en) 2011-12-07
EP2496695A1 (en) 2012-09-12
MX2012005430A (en) 2012-06-19
RU2012122700A (en) 2013-12-10
BR112012011607A2 (en) 2020-06-02
WO2011057014A1 (en) 2011-05-12
JP2013509866A (en) 2013-03-21
TW201121993A (en) 2011-07-01
KR20120120153A (en) 2012-11-01

Similar Documents

Publication Publication Date Title
IN2012DN03338A (en)
EP2566890A4 (en) Anti-pai-1 antibodies and methods of use thereof
JO3118B1 (en) Structures and methods of complementary C5 protein targeting antibodies
CY1122978T1 (en) ANTI-VLA-4 ANTIBODIES
MX2018010572A (en) Hetero-dimeric immunoglobulins.
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
MX2013001473A (en) Antibodies against il-18r1 and uses thereof.
PH12013502230A1 (en) Multispecific antibodies
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
EA201201000A1 (en) METHODS OF TREATMENT OF COLORECTAL CANCER
PL3002298T3 (en) Anti-factor xi monoclonal antibodies and methods of use thereof
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
IN2014KN00848A (en)
BR112013020500A2 (en) isolated, recombinant or purified antibody
CY1121167T1 (en) IMPROVED ANTIBODIES AGAINST HUMAN FRACTALKIN AND THEIR USES
MX336001B (en) Anti-axl antibodies and methods of use.
MX2012011829A (en) Anti-polyubiquitin antibodies and methods of use.
MX2014002053A (en) Anti-mcsp antibodies.
EA201490778A1 (en) ANTIBODIES AGAINST HtrA1 AND METHODS OF APPLICATION
MX2014000363A (en) Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses.
MX2011010012A (en) Novel anti-î+-5î²1 antibodies and uses thereof.
MX346500B (en) Methods and compositions for neural disease immunotherapy.
MY161868A (en) Anti-bv8 antibodies and uses thereof
PH12013500616A1 (en) Antibody compositions and methods of use